ADC Therapeutics SA
Pyrrolobenzodiazepine-antibody conjugates

Last updated:

Abstract:

The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

Status:
Grant
Type:

Utility

Filling date:

25 Nov 2015

Issue date:

22 Sep 2020